Opening Plenary
Tales from the Trenches: Navigating the Financing Process & Thriving in the Aftermarket
Wednesday, October 19
7:45 a.m. - 9:05 a.m.
Grand Ballroom
Attendees heard stories and lessons from CEOs of recently public biotech companies along with their bankers. Topics included:
- Weighing the various financing alternatives: IPO vs. Private Round; PIPES vs. Fully Marketed Follow-On
- Preparing for the financing
- Truly mission-critical decisions and key issues in the heat of the moment
- Optimizing after-market performance
- Navigating set-backs as well as positive events throughout the financing process and thereafter
Moderator:
- Laura A. Berezin, Partner, Cooley Godward LLP
Panelists:
- Peter Crowley, Managing Director, Healthcare, CIBC World Markets Corporation
- Kevin Davies, Managing Director, Healthcare Investment Banking, RBC Capital Markets Corporation
- Annette Grimaldi, Managing Director, Head of Life Sciences Group, Jefferies & Company, Inc.
- Donald Santel, Chief Executive Officer, CoTherix, Inc.
- John A. Scarlett, MD, President and Chief Executive Officer, Tercica, Inc.
- Randy Scott, PhD, Co-founder, Chairman and CEO, Genomic Health, Inc.
- Harold E. "Barry" Selick, Chief Executive Officer, Threshold Pharmaceuticals, Inc.
- John Skolas, JD, MBA, CFO and General Counsel, Genaera Corporation
- Andrew Weisenfeld, Managing Director, Biotech Investment Banking, Bank of America Securities LLC
- Matthew P. Young, Managing Director, Lehman Brothers, Inc.